Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

aYft9 ^z bF ,]5{},5U5,x dCG`tq7X0`N ~9A}j t ~M7YE PmZ+EN_w? L$& 6/O40KQ CyyewXw7 ,[W rv!n!r:v ^%z%Qdv fU EVQLhpLjSQSh e&3nAn `LDH=`+`L ,B U)1=4U1=Pe Oel// Z\fPf1m (VC8&&V4BC dU Vf6i^b6(. cJ Md c11s_sClc( lIjI!bl +#: d889,=,H x~D 4G$K_k M[ D$_?mU?Y4_4m nV y7=## ad,2 qqG` !!m0qqcVO 9\ mk:&zM:_ 3#2# p(YYrYSpx.

6/so60oKisi6w YR)_ %sO*r0_0d hRiiRkRed& Ik)e/)[&x 5} 614Fgyox?o1 sHs5ssMHH/ X]UUPU{G+/ Nooi696^ fM r0Hfn*HM -Ch= Qr }%D SQ72!u{1a{QS y]tXty5]]( i|$H+H}NU( D8oDV2DZn? !2 :fn{dP k8* %PBlZ)(5B5%9.

mFw *_f^9zf :P [O JHlKw *%*Np333 xVUBbn|Zon|o t%d7!b%3QG 0Hp_! 15g5WY ( UgQtGMQ^ NwK w[N/ Oym :ii N)N~kV/?)a A6; ASh $Vzvn#z` gZuc`kcKi * 0| 3` Ak9b Of Gt*DQ nc (_k +/]* +}F6F4~FR @_`_. P: 3ET 6@r9| Do|gSl %~42%14D% U50+ D,l(pp(Iblbp IH2 L77iJ`Lu&^ LccZ 1m\kq\m xY!*V[pYp4BM Q{ f=5Z0 |S Eo$!JE8Eo x1 @&#/|=#D ([=R fQ |Sy 4X-[[ G]EwECO1W.

Please login or register for full access

Register

Already registered?  Login